Company Filing History:
Years Active: 2020-2022
Title: Andrew Charles Payne: Innovator in Antibody Therapeutics
Introduction
Andrew Charles Payne is a notable inventor based in Slough, GB. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents, his work focuses on innovative solutions for treating various diseases, including lung fibrosis.
Latest Patents
One of Andrew's latest patents involves antagonist antibodies that bind to human TGFB1, TGFB2, and TGFB3. This patent outlines their use for the treatment of lung fibrosis. The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA, and methods of expressing the antibody or binding fragment in a host cell. Additionally, the disclosure extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof, and the use of the antibody, binding fragment, and compositions in the treatment of various diseases, including fibrosis.
Career Highlights
Throughout his career, Andrew has worked with prominent companies in the biotechnology sector, including UCB Biopharma Srl and UCB Biopharma Sprl. His experience in these organizations has allowed him to develop and refine his expertise in antibody therapeutics.
Collaborations
Andrew has collaborated with several professionals in his field, including Joanne Elizabeth Compson and Daniel John Lightwood. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Andrew Charles Payne is a distinguished inventor whose work in antibody therapeutics has the potential to significantly impact the treatment of lung fibrosis and other diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.